Spravato in 2026: Monotherapy Approval, Generic Timeline, and Real Cost

If you're researching Spravato in 2026, two questions come up almost universally: did anything actually change recently? and is a cheaper generic version coming? The honest answers, with the data current as of mid-2026 — yes, the FDA approved Spravato as monotherapy in January 2025, and the generic timeline is much less clear than most patients assume, with estimates ranging from 2028 to 2040 depending on which patent is challenged — meaningfully reshape the decision for a lot of patients with treatment-resistant depression who looked at this option a year or two ago and dismissed it.

This is the 2026 update. What's actually different, what's the same, and how the cost reality compares to the at-home alternative that exists alongside it.

What changed in 2025

The single biggest shift in the esketamine landscape since 2019 happened on January 21, 2025, when the FDA approved Spravato as a monotherapy for treatment-resistant depression in adults. The original 2019 approval required patients to be on an oral antidepressant simultaneously; Spravato was approved only as an add-on. The monotherapy approval removes that constraint.

The approval was based on the Phase 4 trial TRD4005, which randomized patients with treatment-resistant depression to twice-weekly intranasal Spravato (56 mg or 84 mg) or placebo for four weeks. The result: 22.5% remission at week 4 with esketamine monotherapy versus 7.6% with placebo, with significant improvement in depressive symptoms within 24 hours of the first dose.

In practical terms, this matters for three groups:

1. Patients who couldn't tolerate oral antidepressants. Side effects (sexual dysfunction, weight gain, emotional blunting, GI issues) cause meaningful numbers of patients to discontinue SSRIs and SNRIs. Before January 2025, those patients were excluded from Spravato eligibility under the FDA label even if Spravato itself was working. Now they're not.
2. Patients who failed multiple oral antidepressants. The same logic: if you've cycled through three or four SSRIs/SNRIs without sustained benefit, the requirement to remain on one alongside Spravato felt like piling on. The monotherapy approval acknowledges that.
3. Patients in a maintenance phase who responded well to Spravato and want to taper off the oral antidepressant. Previously this would have been off-label; now it's within the FDA label.

The dosing schedule (twice-weekly induction for 4 weeks, then weekly for 4 weeks, then every-1-or-2-weeks maintenance) is unchanged.

What did NOT change: the requirement that Spravato be administered in a REMS-certified clinic with a 2-hour post-dose observation period. That's structural to the dissociative side effects and isn't going away.

The generic esketamine question (probably the most-asked)

Patients ask this constantly: when does the patent expire, when does a generic come out, will it cut the cost?

The honest 2026 answer is more nuanced than most online summaries suggest:

• Johnson & Johnson holds a layered patent portfolio on Spravato. The FDA Orange Book and J&J's published expiration tables list patents expiring in 2027, 2031, 2034, and 2035 covering different aspects of composition and method-of-use.
• Estimated earliest generic entry: as early as January 2028 per DrugPatentWatch, if a paragraph IV challenge against the earlier-expiring patents succeeds and is upheld. As of 2026, no Abbreviated New Drug Application (ANDA) for esketamine nasal spray has been publicly filed or accepted for FDA review.
• Estimated latest generic entry: February 2040 per Pharsight's projection, accounting for method-of-use patents and regulatory exclusivities that may extend protection on the specific nasal-spray-for-TRD indication.
• The honest range is 2 to 14 years from today. Patients shouldn't bet on a specific date.

If you're weighing Spravato cost against "I'll just wait for the generic," the wait could be short or very long. Most active treatment-resistant depression cases shouldn't defer treatment on a generic-launch bet.

What Spravato actually costs in 2026

The pricing landscape has more variation than the list-price headline suggests:

Without insurance (cash-pay)

• Per-dose list price: $590–$885 depending on dose strength (56 mg or 84 mg) and the device delivery configuration.
• First-month cost (induction, 8 doses): $4,000–$6,000.
• Subsequent maintenance: ~$1,000–$1,800/month depending on maintenance frequency.
• First-year total: $14,000–$24,000 depending on dose, frequency, and which maintenance cadence the prescriber settles on.
• REMS-certified clinic fees on top of the drug cost — the 2-hour observation requirement means the facility bills for nursing time, vitals monitoring, and the room. Typically $50–$200 per visit.

With commercial insurance

Most major insurers (Aetna, Cigna, BCBS plans, Anthem, United, Medicare Advantage) cover Spravato for documented TRD with prior authorization. Post-deductible:

• Typical out-of-pocket: $10–$50 per dose.
• Janssen CarePath Savings Program — the single biggest cost-reduction lever most patients miss. Available to patients with commercial insurance, the program can reduce out-of-pocket cost to as low as $10 per session, with up to $7,150 in eligible copay assistance per calendar year. Most enrolled patients report under $200 total out-of-pocket for the entire induction course.

With Medicare

Medicare covers Spravato as a Part B physician-administered drug. After Part B deductible, Medicare pays 80% and you owe 20% coinsurance, which works out to roughly $140–$240 per session depending on dose. A Medicare supplemental (Medigap) plan can cover most or all of the 20% coinsurance.

The bottom line on Spravato cost

For an insured patient with commercial coverage and a TRD diagnosis who enrolls in Janssen CarePath, Spravato is often the cheapest legitimate ketamine therapy path available. For an uninsured cash-pay patient, it's by far the most expensive. The variance between those two scenarios is enormous, which is why generic cost summaries are usually misleading — your real cost is heavily plan-specific.

What changed about access in 2026

Two structural shifts worth knowing:

REMS-certified facility availability has grown. In 2019, accessing Spravato required driving to one of a few hundred specialized psychiatric clinics. By 2026, Florida has around 23 REMS-certified sites and New Jersey has its own established footprint. The official SPRAVATO REMS Treatment Center Locator at spravato.com gives the current list near any ZIP code. Travel burden is meaningfully lower than it was.

Mobile and concierge Spravato programs have started appearing. A small number of physician practices send a nurse to the patient's home with the REMS-required monitoring equipment, run the dose in the patient's bedroom, and stay for the 2-hour observation. This is still a niche, mostly in major metros, and meaningfully more expensive than going to a clinic. But it exists.

What didn't change: Spravato cannot be self-administered or used outside a REMS-certified setting. The dose must be supervised. This is a structural difference from at-home compounded sublingual ketamine, where supervised administration happens in the home with a peer supervisor under the prescribing physician's protocol.

How Spravato compares to compounded sublingual ketamine in 2026

The choice still mostly comes down to insurance, time, and severity. The fast version:

• If you have strong commercial insurance, can enroll in Janssen CarePath, have an established TRD diagnosis, and time to attend twice-weekly clinic visits during the induction phase, Spravato is often the cheapest path with the strongest evidence base.
• If you're cash-pay or underinsured, want to do treatment at home with a peer supervisor, and have a treatment-resistant condition without immediate suicidality, compounded sublingual ketamine at $250–$500/month is the lower-cost alternative.
• If you've already failed Spravato or didn't respond adequately, compounded ketamine is on the table; some patients respond to one and not the other despite the shared active ingredient.

For a deeper side-by-side, our existing Spravato vs compounded ketamine post covers the mechanism, dosing, and decision logic in more detail. For affordability questions, affordable ketamine therapy covers what corners are safe to cut and which aren't.

What about other 2026 alternatives to Spravato?

The landscape of psychedelic-adjacent and rapid-acting antidepressants in 2026 has more options on paper than it had in 2019, but most are not clinically available for general TRD yet:

• Brexanolone (Zulresso) is FDA-approved for postpartum depression specifically, not general TRD. IV infusion in a hospital setting.
• Zuranolone (Zurzuvae), a successor to brexanolone, was FDA-approved in 2023 for postpartum depression. Oral, 14-day course. Again, postpartum-specific.
• MM120 (lysergide d-tartrate) is in late-stage trials for generalized anxiety disorder. Not yet FDA-approved as of 2026.
• Psilocybin completed Phase 3 trials but has not received FDA approval as of mid-2026; under FDA review.
• MDMA-assisted psychotherapy received a Complete Response Letter from the FDA in 2024 requiring additional study; not approved.

For an adult with treatment-resistant unipolar depression in 2026 who's looking at FDA-approved rapid-acting options, the actual list is short: Spravato or off-label ketamine (IV, IM, or sublingual). Most of the other options that get media coverage are either not yet approved or have narrow indications.

When Spravato is still the right call in 2026

After the monotherapy approval, Spravato moved up the consideration list for a meaningfully bigger group of patients. The specific situations where I'd point a patient toward Spravato in 2026:

• Strong commercial insurance, established TRD (failed 2+ antidepressants), prior auth clears, and patient willing to enroll in Janssen CarePath
• Acute suicidality or severe symptom intensity needing the strongest evidence base
• Patients who failed compounded ketamine or had inadequate response to sublingual administration (the intranasal route hits faster and harder, which sometimes matters)
• Patients who specifically prefer in-clinic administration with structured 2-hour observation
• Patients in REMS-certified facility coverage areas without significant travel burden
• Medicare beneficiaries with Medigap supplemental coverage that absorbs the 20% coinsurance

For everyone else — particularly cash-pay patients, patients with mild-to-moderate TRD who want to start low and titrate, patients with time constraints (job, kids) that make twice-weekly clinic visits difficult, patients in rural areas without easy access to a REMS facility — at-home compounded ketamine remains the more practical entry point.

Frequently Asked Questions

Is Spravato approved as a monotherapy in 2026?

Yes. The FDA approved Spravato (esketamine nasal spray) as a monotherapy for treatment-resistant depression in adults on January 21, 2025, based on the Phase 4 TRD4005 trial. The original 2019 approval required co-administration with an oral antidepressant; the 2025 approval removed that requirement.

When will a generic version of Spravato be available?

The honest answer is "anywhere from 2028 to 2040." Johnson & Johnson holds a layered patent portfolio with patents expiring in 2027, 2031, 2034, and 2035 per the FDA Orange Book. DrugPatentWatch estimates earliest generic entry as early as January 2028 if a successful paragraph IV challenge happens; Pharsight's more conservative estimate, factoring in method-of-use patents and regulatory exclusivities, projects February 2040. No ANDA for generic esketamine is currently in FDA review. Patients shouldn't defer treatment on a specific generic-launch bet.

How much does Spravato cost in 2026?

Cash-pay list runs $590–$885 per dose; first-month induction (8 doses) costs $4,000–$6,000; total first-year cash-pay is $14,000–$24,000. With commercial insurance and Janssen CarePath enrollment, out-of-pocket drops to as low as $10 per session, with up to $7,150 in eligible copay assistance per calendar year. Most insured patients enrolled in CarePath report under $200 out-of-pocket for the entire induction course. Medicare beneficiaries owe 20% coinsurance, roughly $140–$240 per session, which a Medigap plan can cover.

What is the Janssen CarePath Savings Program?

It's the manufacturer's copay assistance program for commercially insured patients. Enrollment can reduce out-of-pocket cost to as low as $10 per session, with annual benefit up to $7,150. Not available to patients on government insurance (Medicare, Medicaid, VA, Tricare). If you have commercial insurance, this is the single largest lever available to make Spravato affordable, and most insured patients dramatically over-estimate their out-of-pocket cost because they don't know it exists.

Can I do Spravato at home in 2026?

Generally no. Spravato must be administered in a REMS-certified facility with a 2-hour post-dose observation period. A small number of concierge practices offer in-home Spravato with a visiting nurse and monitoring equipment in major metros, but this is niche and significantly more expensive than going to a clinic. Compounded sublingual ketamine prescribed by a physician with a home peer supervisor is the lower-cost at-home alternative.

Does insurance cover Spravato in 2026?

Most major commercial insurers (Aetna, Cigna, BCBS, Anthem, United) cover Spravato for documented TRD with prior authorization. Documentation typically requires evidence of failure of at least 2 adequate antidepressant trials. Medicare covers Spravato under Part B. Coverage for compounded ketamine remains essentially nonexistent — that's an off-label compounded medication, which is structurally outside standard insurance coverage.

Is Spravato more effective than compounded ketamine?

The honest answer is "for the FDA-approved indication of TRD, the evidence base is stronger for Spravato because it has the pivotal trials and FDA approval." Real-world response rates for both products in TRD are broadly similar in patient populations who have access to either; the bigger predictors of response are dose, duration of treatment, and integration with psychotherapy rather than the specific molecule.

What's the timeline difference between Spravato induction and at-home ketamine?

Spravato induction is twice-weekly clinic visits for 4 weeks (8 doses), then weekly for 4 weeks (4 doses), then maintenance every 1–2 weeks indefinitely. Each visit takes 2.5+ hours including the observation period. At-home compounded sublingual ketamine is typically 1–2 sessions per week for 4–8 weeks of induction, then maintenance every 2–6 weeks. Each at-home session takes ~3 hours from dose to return to baseline. Time burden is similar; location differs (clinic vs home).

What if I've already tried Spravato and it didn't work?

Some patients who respond inadequately to Spravato respond better to compounded sublingual ketamine, and vice versa. The reasons aren't fully understood but may relate to pharmacokinetic differences between the racemic mixture (in compounded ketamine) and the isolated S-enantiomer (esketamine in Spravato), or to differences in dose titration flexibility. If Spravato didn't work for you, discussing at-home sublingual ketamine with a prescribing physician is a reasonable next step.

Ready to Discuss Your Options?

If you're weighing Spravato against the at-home compounded ketamine alternative and want a physician's read on which fits your specific situation, I'm happy to take a look. Dr. Ben Soffer is a board-certified physician providing personalized, discreet at-home ketamine therapy for depression, anxiety, PTSD, and chronic pain.

Check Your Eligibility →

Discreet Ketamine provides at-home ketamine therapy to residents of Florida and New Jersey. All treatments are supervised by Dr. Ben Soffer, a board-certified physician. This post is informational and does not constitute medical advice; consult your own prescribing physician about whether Spravato or compounded ketamine is appropriate for your situation.